Key result
Continuous intravenous nitroglycerin (0.5 microg/kg/min) decreased systolic flow by 89.9% (p<0.01) and increased diastolic flow by 74.2% (p<0.05) without reducing total coronary flow.
Why the study?
Does continuous intravenous nitroglycerin affect coronary blood flow and vascular resistance in patients with atypical chest pain?
Does continuous intravenous nitroglycerin affect coronary blood flow and vascular resistance in patients with atypical chest pain?
Continuous intravenous nitroglycerin maintains subendocardial blood flow despite reducing coronary perfusion pressure in patients with atypical chest pain.
Does not support practice change for nitroglycerin; leaves open whether diastolic flow shift benefits ischemic patients.
To examine the responses of coronary conduit and resistance arteries to the continuous i.v. administration of nitroglycerin in 15 patients with atypical chest pain, we measured coronary blood flow velocity in the left anterior descending coronary artery using a Doppler guide wire and the lumen diameter and cross-sectional area by quantitative coronary angiography. Systolic flow, diastolic flow, total coronary flow, and coronary vascular resistance were calculated. Stepwise increases in dose of nitroglycerin resulted in significant dose-dependent decrease in mean aortic pressure (p < 0.01) and increase in lumen diameter (p < 0.05). After nitroglycerin administration of 0.5 microg/kg/min, systolic flow decreased significantly by 89.9+/-15.7% (p < 0.01), and diastolic flow increased significantly by 74.2+/-37.1% (p < 0.05). Total coronary flow did not change significantly with the various doses of nitroglycerin. However, coronary vascular resistance decreased significantly at concentrations greater than 0.5 microg/kg/min nitroglycerin. Continuous nitroglycerin infusion did not reduce either diastolic or total coronary blood flow despite a significant reduction in coronary perfusion pressure. These results indicate that subendocardial blood flow might be maintained during continuous i.v. infusion of nitroglycerin within the clinical dose range.
No takes yet. Share an insight, caveat, or question.
Kawabata et al. (2000) studied atypical chest pain (n=15). Continuous intravenous nitroglycerin was evaluated on Responses of coronary conduit and resistance arteries (coronary blood flow velocity, lumen diameter, cross-sectional area). Continuous intravenous nitroglycerin (0.5 microg/kg/min) decreased systolic flow by 89.9% (p<0.01) and increased diastolic flow by 74.2% (p<0.05) without reducing total coronary flow.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: